Patent · US Active

Quinazoline derivatives for the treatment of cancer diseases

US9089571B2 · kind B2 · utility

2Cited by

32References

3Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Flavio Solca · Wien, AT
Andree AMELSBERG · Southbury, US
Jacobus Van Meel · Biberach, DE
Anke Baum · Alland, AT
Gerd Stehle · Heidelberg, DE

Key dates

Filing date	Feb 14, 2013
Grant date	Jul 28, 2015
Priority date	—
Expiry date	Feb 14, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the use of quinazolines of formula (I),wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.